Cerebrospinal fluid concentrations of antituberculosis agents in adults and children

Tuberculosis

Volumn 90, Issue 5, 2010, Pages 279-292

  Donald, P R ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Antituberculosis; Cerebrospinal fluid; Chemotherapy; Pharmacokinetics; Tuberculous meningitis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; CIPROFLOXACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ACETYLATOR PHENOTYPE; ADULT; BACTERIAL MENINGITIS; CHILD; DRUG ABSORPTION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG PENETRATION; HUMAN; LIVER TOXICITY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETROBULBAR OPTIC NEUROPATHY; REVIEW; SINGLE DRUG DOSE; TUBERCULOUS MENINGITIS;

ADULT; ANTITUBERCULAR AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; ISONIAZID; MALE; PYRAZINAMIDE; RIFAMPIN; TUBERCULOSIS, MENINGEAL;

EID: 77957192120     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2010.07.002     Document Type: Review

References (111)

1. G.E. Thwaites, N.D. Bang, N.H. Dung, H.T. Quy, D.T.T. Oanh, and N.T.C. Thoa Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults N Eng J Med 351 2004 1741 1751
2. R. Norrby Pharmacokinetic aspects of the treatment of infections of the central nervous system J Antimicrob Chemothr 5 1979 630 633
3. R. Nau, F. Sörgel, and W. Prange Pharmacokinetic optimization of the treatment of bacterial central nervous system infections Clin Pharmacokin 35 1998 223 246
4. N. Rastogi, V. Labrousse, and K.S. Goh In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against virulent H37 Rv strain in human macrophages Curr Microbiol 33 1996 167 175
5. P.R. Donald, and A.H. Diacon The early bactericidal activity of anti-tuberculosis drugs: a literature review Tuberculosis 88 2008 S75 S83
6. D.A. Mitchison Role of individual drugs in the chemotherapy of tuberculosis Int J Tuberc Lung Dis 4 2000 796 806
7. R.S. Mitchell, and J.C. Bell Clinical implications of isoniazid blood levels in pulmonary tuberculosis N Eng J Med 257 1957 1066 1070
8. P.R. Donald, F.A. Sirgel, A. Venter, D.P. Parkin, H.I. Seifart, and B.W. van de Wal The influence of human N-acetyltransfearase genotype on the early bactericidal activity of isoniazid Clin Infect Dis 39 2004 1425 1430
9. P.R. Donald, D.P. Parkin, H.I. Seifart, H.S. Schaaf, P.D. van Helden, and C.J. Werely The influence of dose and N-acetyltransferase genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid Eur J Clin Pharmacol 63 2007 633 639
10. Tuberculosis Chemotherapy Centre, Madras A concurrent comparison of isoniazid plus PAS with three regimens of isoniazid alone in the domiciliary treatment of pulmonary tuberculosis in South India Bull Wld Hlth Org 23 1960 535 585
11. C.A. Peloquin Therapeutic drug monitoring: principles and applications in mycobacterial infections Drug Ther 22 1992 31 36
12. D.F. Elmendorf, W.U. Cawthon, C. Muschenheim, and W. McDermott The absorption, distribution, excretion, and short-term toxicity of isonicotinic acid hydrazide (nydrazid) in man Am Rev Tuberc 65 1952 429 442
13. W.R. Barclay, R.H. Ebert, G.V. le Roy, R.W. Manthei, and L.J. Roth Distribution and excretion of radioactive isoniazid in tuberculosis patients JAMA 151 1953 1384 1388
14. A.P. Fletcher CSF-isoniazid levels in tuberculosis meningitis Lancet 2 1953 694 696
15. E.D. Pellegrino, F.G. Petrik, and R. Horton The treatment of tuberculosis meningitis in infants with streptomycin and isonicotinic acid hydrazide (isoniazid) Dis Chest 26 1954 146 165
16. V.S. Lanier, W.F. Russel, A. Heaton, and A. Robinson Concentrations of active isoniazid in serum and cerebrospinal fluid of patients with tuberculosis treated with isoniazid Pediatrics 21 1958 910 914
17. R. Forgan Smith, G.A. Ellard, D. Newton, and D.A. Mitchison Pyrazinamide and other drugs in tuberculosis meningitis Lancet 2 1983 374
18. S.-G. Shin, J.-K. Roh, N.-S. Lee, J.-G. Shin, I.-J. Jang, and C.-W. Park Kinetics of isoniazid transfer into cerebrospinal fluid in patients with tuberculous meningitis J Korean Med Sci 5 1990 39 45
19. S. Kaojarern, K. Supmonchai, P. Phuapradit, C. Mokkhavesa, and S. Krittiyanunt Effect of steroids on cerebrospinal fluid penetration of antituberculosis drugs in tuberculosis meningitis Clin Pharmacol Ther 49 1991 6 12
20. P.R. Donald, W.L. Gent, H.I. Seifart, J.H. Lamprecht, and D.P. Parkin Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status Pediatrics 89 1992 247 250
21. G.A. Ellard, M.J. Humphries, and B.W. Allen Cerebrospinal fluid drug concentrations and the treatment of tuberculosis meningitis Am Rev Respir Dis 148 1993 650 655
22. G. Ricci, T. Copaitich, and D. Curatolo Le concentrazioni dell'isoniazide nel sangue e nel liquor in rapporto a varie dosi orali Minerva Med 45 1954 657 664
23. W.W. Weber The genetics of acetylation The acetylator genes and drug responses 1987 Oxford University Press New York 32 49
24. East African/British Medical Research Council Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report Lancet 2 1974 237 240
25. Hong Kong Chest Service/British Medical Research Council Controlled trial of 2, 4 & 6 months of pyrazinamide in a 6-month, 3-times weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide Am Rev Resp Dis 143 1991 700 706
26. G. Acocella, V. Pagani, M. Marchetti, G.C. Baroni, and F.B. Nicolis Kinetic studies on rifampicin Chemotherapy 16 1971 356 370
27. S. Furesz, R. Scotti, R. Pallanza, and E. Mapelli Rifampicin: a new rifamycin Arzneimittelforschung 17 1967 534 537
28. C.A. Peloquin, R. Namdar, M.D. Singleton, and D.E. Nix Pharmacokinetics of rifampin under fasting conditions, with food and with antacids Chest 115 1999 12 18 (Pubitemid 29047048)
29. G.P. Vello, and G. Vittori Ricerche sull'assorbimento orale e sulla eliminaxione urinaria della rifampicina Gaz Intern Med Chirurg 73 1968 2799 2804
30. G. Boman, and V.A. Ringberger Binding of rifampicin by human plasma proteins Eur J Clin Pharmacol 7 1974 369 373
31. W.J. Burman, K. Gallicano, and C. Peloquin Comparative pharmacokinetics and pharmacodynamics of rifamycin antibacterials Clin Pharmacokin 40 2001 327 341
32. J. Chen, and K. Raymond Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor Ann Clin Microb Antimicrob 5 2006 3 10.1186/1476-0711-5-3
33. J. Prakash, V. Thirumurthy, N.P. Jitender, and S.K. Gupta Serum rifampicin levels in patients with tuberculosis Clin Drug Invest 23 2003 463 472
34. M.W. Long, D.E. Snider, and L.S. Farer U.S. Public Health Service trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis Am Rev Respir Dis 119 1979 879 894
35. A. Jindani, V.R. Aber, E.A. Edwards, and D.A. Mitchison The early bactericidal activity of drugs in patients with pulmonary tuberculosis Am Rev Respir Dis 121 1980 939 949
36. S.L. Chan, W.K. Yew, D.J. Ma, D.J. Girling, V.R. Aber, and D. Felmingham The early bactericidal activity of rifabutin measured by sputum viable counts in Honk Kong patients with pulmonary tuberculosis Tubercle Lung Dis 73 1992 33 38
37. F.A. Sirgel, F.J.H. Botha, D.P. Parkin, B.W. Van de Wal, P.R. Donald, and P. Clark The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment J Antimicrob Chemother 32 1993 867 875
38. F.A. Sirgel, P.B. Fourie, P.R. Donald, N. Padayatchi, R. Rustomjee, and J. Levin The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis Am J Respir Crit Care Med 172 2005 128 135
39. D.A. Mitchison Basic concepts in the chemotherapy of tuberculosis P.R.J. Gangadharam, P.A. Jenkins, Mycobacteria II, chemotherapy 1998 Chapman & Hall New York 15 50
40. A.H. Diacon, R.F. Patientia, A. Venter, P.D. van Helden, P.J. Smith, and H. McIlleron Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears Antimicrob Agents Chemother 51 2007 1994 2990
41. G. Curci, F. Della Cava, and L. Vitale Sulla ripartizione fra sangue e liquor della rifampicina AMP Minerva Med 60 1969 2399 2402
42. A. Ninni, F. Della Cava, and L. Vitale La rifampicina nella terapia della meningite tubercolare Riforma Med 85 1971 1349 1351
43. J.J.G. D'Oliviera Cerebrospinal fluid concentrations of rifampin in meningeal tuberculosis Am Rev Respir Dis 106 1972 432 437
44. D. Larbaoui, F. Boulahbal, A. Ait-Khaled, D. Baghbagha, H. Benseman, and S.I. Bensafar Etude des taux sériques et rachidiens de rifampicine (AMP) Arch Inst Pasteur Alger 51-52 1972-1973 171 181
45. R. Woerle, J. Viallier, J.C. Guerin, and A. Bertoye Passage de la rifampicine dans leliquide cephalo-rachidien au cours des meningites tuberculeuses Lyon Med 227 1972 837 845
46. Y. De Rautlin de la Roy, A. Hoppeler, G. Creusot, and A.M. Bruault Taux de rifampicine dans le sérum et le liquide céphalo-racidiene chez l'enfant Arch France Péd 31 1974 477 488
47. J.E. Sippel, I.A. Mikhail, N.I. Girgis, and H. Youssef Rifampin concentrations in cerebrospinal fluid of patients with tuberculosis meningitis Am Rev Respir Dis 109 1974 579 580
48. T.V. Stanley, and V. Balakrishnan Rifampicin in neonatal ventriculitis Aust Paediatr 18 1982 200 201
49. I.A. Mikhail, N.I. Girgis, L.A. Bourgeois, and C.R. Lissner Cerebrospinal fluid serum concentrations of rifampin in meningeal tuberculosis after intravenous administration Chemioterapia 2 1986 309 310
50. J. Woo, M.J. Humphries, K. Chan, G. O'Mahony, and R. Teoh Cerebrospinal fluid and serum levels of pyrazinamide and rifampicin in patients with tuberculosis meningitis Curr Ther Res 42 1987 235 242
51. M.C. Nahata, P. Fan-Havard, W.J. Barson, H.M. Bartkowski, and E.J. Kosnik Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements Eur J Clin Pharmacol 38 1990 515 517 (Pubitemid 20181285)
52. R. Nau, H.W. Prange, S. Menck, H. Kolenda, K. Visser, and J.K. Seydel Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges J Antimicrob Chemother 29 1992 719 724
53. M. Mahajan, D. Rohatgi, V. Talwar, S.K. Patni, P. Mahajan, and D.S. Agarwal Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculosis meningitis J Commun Dis 29 1997 269 274
54. A. Hedberg, H.-G. Hrdemark, B. Olsson-Liljequist, and J. Sjölin Penetration of fusidic acid and rifampicin into cerebrospinal fluid in low-grade inflammatory meningitis caused by Staphylococcus epidermidis Clin Microbiol Infect 10 2004 765 768
55. G. Acocella, G. Buniva, U. Flauto, and F.B. Nicolis Absorption and elimination of the antibiotic rifampicin in newborns and children Proc 6th Int Congress of chemotherapy; Tokyo 1969 vol. 2 1970 Univ Tokyo Press Tokyo 755 760
56. H.S. Schaaf, M. Willemse, K. Cilliers, D. Labadarios, J.S. Maritz, and G.D. Hussey Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis BMC Med 22 2009 e19
57. G.E. Thwaites, H.T.N. Lan, N.H. Dung, H.T. Quy, D.T. Oanh, and N.T. Thoa Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculosis meningitis J Infect Dis 192 2005 79 88
58. K.D. Stottmeier, R.E. Beam, and G.P. Kubika Determination of drug susceptibility of mycobacteria to pyrazinamide in 7H10 agar Am Rev Respir Dis 96 1967 1072 1075
59. M. Salfinger, and L.B. Heifets Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method Antimicrob Agents Chemother 32 1988 1002 1004
60. D.C. Perlman, Y. Segal, S. Rosenkranz, P.M. Rainey, C.A. Peloquin, and R.P. Remmel The clinical pharmacokinetics of pyrazinamide in HIV-infected patients with tuberculosis Clin Infect Dis 38 2004 556 564
61. S. Chideya, C.A. Winston, C.A. Peloquin, W.Z. Bradford, P.C. Hopewell, and C.D. Wells Isoniazid, rifampin, ethambutol, and pyrazinamide phramacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana Clin Infect Dis 48 2009 1685 1694
62. F. Corsini, and G. Silanos La concentrazione nel liquido cerebro-spinale della pirazinamide somministrata a dosi terapeutiche Clin Pediatr (Bologna) 39 1957 40 46
63. G.A. Ellard, M.J. Humphries, M. Gabriel, and R. Teoh Penetration of pyrazinamide into the cerebrospinal fluid in tuberculosis meningitis Br Med J 294 1987 284 285 (Pubitemid 17006325)
64. P.R. Donald, and H.I. Seifart Cerebrospinal fluid pyrazinamide concentrations in children with tuberculosis meningitis Pediatr Infect Dis J 7 1988 469 471
65. P. Phuapradit, K. Supmonchai, S. Kaojarern, and C. Mokkhavesa The blood/cerebrospinal fluid portioning of pyrazinamide: a study during the course of treatment of tuberculosis meningitis J Neurol Neurosurg Psychiatr 53 1990 81 82
66. S.E. Berning, T.A. Cherry, and M.D. Iseman Novel treatment of meningitis caused by multidrug-resistant Mycobacterium tuberculosis with intrathecal levofloxacin and amikacin: case report Clin Infect Dis 32 2001 643 646
67. World Health Organization Stop TB Department Treatment of tuberculosis: guidelines for national programmes 3rd ed. 2003 World Health Organization Geneva
68. Medical Research Council Streptomycin in tuberculosis trials committee. Streptomycin treatment of tuberculosis meningitis Lancet 254 1948 582 596
69. J.P. DeVincenzo, S.E. Berning, C.A. Peloquin, and R.N. Husson Multidrug-resistant tuberculosis meningitis: clinical problems and concentrations of second-line antituberculosis medications Ann Pharmacother 33 1999 1184 1188
70. W.P. Boger, and J.J. Gavin Kanamycin: its cerebrospinal fluid diffusion, renal clearance, and comparison with streptomycin N.H. Welch, F. Marti-Ibanez, Antibiotics annual 1958-59 1959 Medical Encyclopaedia New York 677 683
71. H.F. Eichenwald Some observations on dosage and toxicity of kanamycin in premature and full-term infants Ann NY Acad Sci 132 1966 991 994
72. O. Brückner, H. Collman, and H.G. Hoffmann CSF levels of amikacin following systemic application in patients with slightly and severely impaired cerebrospinal barrier Immun Infect 10 1982 76 81
73. H.E. James, H.D. Wilson, J.D. Connor, and J.W. Walsh Intraventricular cerebrospinal fluid antibiotic concentrations in patients with intraventricular infections Neurosurgery 10 1982 50 54
74. H. Trujillo, H. Salgado, A. Uribe, N. Agudelo, C.T. Zapata, and E.L. de Vidal Amikacin concentration in the cerebrospinal fluid of children with acute bacterial meningitis J Int Med Res 7 1979 45 51
75. J.-L. Gaillard, C. Silly, A. Le Masne, B. Mahut, F. Lacaille, and G. Cheron Cerebrospinal fluid penetration of amikacin in children with community acquired bacterial meningitis Antimicrob Agents Chemother 39 1995 253 255
76. A. Upton, A. Woodhouse, R. Vaughan, S. Newton, and R. Ellis-Pegler Evolution of central nervous system multidrug-resistant Mycobacterium tuberculosis and late relapse of cryptic prosthetic hip joint tuberculosis: complications during treatment of disseminated isoniazid-resistant tuberculosis in an immunocompromised host J Clin Microbiol 47 2009 507 510
77. R.G. Shepherd, and R.G. Wilkinson Antituberculosis agents. II. N, N'-diisopropylethylenediamine and analogs J Med Chem 5 1962 823 835
78. R.E. Carr, and P. Henkind Ocular manifestations of ethambutol Arch Opthal 67 1962 566 571
79. V.A. Place, M.M. Pyle, and J. de la Huerga Ethambutol in tuberculosis meningitis Am Rev Respir Dis 99 1969 783 785
80. J.A. Pilheu, F. Maglio, R. Cetrangolo, and A.D. Pleus Concentrations of ethambutol in the cerebrospinal fluid after oral administration Tubercle 52 1971 117 122
81. I.D. Bobrowitz Ethambutol in tuberculosis meningitis Chest 61 1972 629 632
82. U. Gundert-Remy, M. Klett, and E. Weber Concentration of ethambutol in cerebrospinal fluid in man as a function of the non-protein-bound drug fraction Eur J Clin Pharmacol 6 1973 13 136
83. M. Tsukamura, E. Nakamura, S. Yoshi, and H. Amano Therapeutic effect of a new antibacterial substance ofloxacin (DL-8280) on pulmonary tuberculosis Am Rev Respir Dis 131 1985 352 356 (Pubitemid 15133592)
84. P.A. Willcox, P.J. Groenewald, and C.R. Mackenzie Ofloxacin-based chemotherapy in multiply drug-resistant pulmonary tuberculosis Drugs 45 1993 16 17
85. Tuberculosis Research Centre Shortening short course chemotherapy: a randomized clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase Ind J Tuberc 49 2002 27 38
86. R. Kitzes-Cohen, A. Miler, A. Gilboa, and D. Harel Penetration of ciprofloxacin into the cerebrospinal fluid Rev Infect Dis 10 1988 S256 S257
87. M. Wolff, L. Boutron, E. Singlas, B. Clair, J.M. Decazes, and B. Regnier Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis Antimicrob Agents Chemother 31 1987 899 902
88. R. Nau, H.W. Prange, J. Martell, S. Sharifi, H. Kolenda, and J. Bircher Penetration of ciprofloxacin into the cerebrospinal fluid of patients with uninflammed meninges J Antimicrob Chemother 25 1990 965 973
89. J.P. Stahl, J. Croize, Lefbvre, J.P. Bru, A. Guyot, and D. Leduc Diffusion of ofloxacin into the cerebrospinal fluid in patients with bacterial meningitis Infection 14 suppl 4 1986 S254 S255
90. G. Stübner, W. Weinrich, and U. Brands Study of the cerebrospinal fluid penetrability of ofloxacin Infection 14 1986 S250 S253
91. M. Drancourt, H. Gallais, D. Raoult, E. Estrangin, M.N. Mallet, and P. De Micco Ofloxacin penetration into cerebrospinal fluid J Antimocrob Chemother 22 1988 264 265
92. N. Bitar, R. Claes, and P. Van der Auwera Concentrations of ofloxacin in serum and cerebrospinal fluid of patients without meningitis receiving the drug intravenously and orally Antimicrob Agents Chemother 33 1989 1686 1690
93. J.C. Pioget, M. Wolff, M.J. Singlas, M.J. Laisne, B. Clair, and B. Regnier Diffusion of ofloxacin into the cerebrospinal fluid in patients with purulent meningitis or ventriculitis Antimicrob Agents Chemother 33 1989 933 936
94. R. Nau, M. Kinzig, T. Dreyhaupt, H. Kolenda, F. Sörgel, and H.W. Prange Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin Antimocrob Agents Chemother 38 1994 1849 1853
95. S. Luo, J. Lei, R. Zhang, H. Cai, and R. Li Determination of levofloxacin in plasma and cerebrospinal fluid with HPLC and its pharmacokinetics in patients undergoing neurosurgical operations Yao Xue Xue Bao 33 1998 937 940
96. F. Pea, F. Pavan, E. Nascimben, C. Benetton, P.G. Scotton, and A. Vaglia Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy Antimicrob Agents Chemother 47 2003 3104 3108
97. J.W.C. Alffenaar, M. de Vries, G.J. Luijckx, D. van Soolingen, T.S. van der Werf, and R. van Altena Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculosis meningitis Antimicrob Agents Chemother 52 2008 2293 2295
98. K. Kannelakopoulou, A. Pagoultou, K. Struompolis, M. Vafiadou, H. Kranidioti, and H. Giamarellou Pharmacokinetics of moxifloxacin in no-inflammed cerebrospinal fluid of humans: implication for bactericidal effect J Antimicrob Chemother 61 2008 1328 1331
99. J.W.C. Alffenaar, R. van Altena, H.J. Bõkkerink, G.J. Luijckx, D. van Soolingen, and R.E. Aarnoutse Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis Clin Infect Dis 49 2009 1080 1082
100. E. Silber, P. Sonnenberg, D. Saffer, and H.J. Koornhof Multidrug-resistant tuberculosis meningitis in a health care worker Int J Tuberc Lung Dis 2 1998 774 776
101. N. Padayatchi, S. Bamber, H. Dawood, and R. Bobat Multidrug-resistant tuberculosis meningitis in children in Durban, South Africa Pediatr Infect Dis J 25 2006 147 150
102. N. Rist, F. Grumbach, and D. Libermann Experiments on the antituberculosis activity of alpha-ethyl-thioisonicotinamide Am Rev Tuberc Pulmon Dis 79 1959 1 5
103. W.S. Schwartz Comparison of ethionamide with isoniazid in original treatment cases of pulmonary tuberculosis Am Rev Respir Dis 93 1966 685 692
104. I.E. Hughes, H. Smith, and P.O. Kane Ethionamide: its passage into the cerebrospinal fluid in man Lancet 1 1962 616 617
105. P.R. Donald, and H.I. Seifart Cerebrospinal fluid ethionamide concentrations in children with tuberculosis meningitis J Pediatr 115 1989 483 486
106. Anonymous Antituberculosis drugs in meningitis Br Med J 2 1963 165
107. S. Kernbaum Treatment of tuberculous meningitis J Pediatr 87 1975 837
108. J. Fouquet, L. Teyssier, P. Cornu, and V. Heimann Association isoniazide-Éthionamide dans le traitement de la méningite tuberculeuse Rev Tuberc Pneumol 26 1962 469 487
109. K.G.S. Nair, I.G. Epstein, H. Baron, and M.G. Mulinos Absorption, distribution and excretion of cycloserine in man Antibio Ann 1955-1956 1956 136 140
110. R. Dubois The treatment of acute tuberculosis in childhood The treatment of tuberculosis in childhood 1956 Centre International de L'Enfance, Travaux et Documents-X Paris 155 193
111. R. Spector, and A.V. Lorenzo The active transport of para-aminosalicylic acid from the cerebrospinal fluid J Pharmacol Exp Ther 185 642 1973 642 648